Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results

 ●Q3 Revenue of $9.1 million; an 11% increase year-over-year ●Q3 Test volume up 11% year-over-year ●Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial...

Related Keywords

United States ,Chris Mccarthy ,Interpace Bioscience ,Tom Burnell ,Interpace Biosciences ,Company Medicare ,Exchange Commission ,Company Line Of Credit ,Globenewswire Inc ,Interpace Biosciences Inc ,Novitas Solutions Inc ,Securities Exchange ,Comerica Bank ,Company Annual Report On Form ,Net Revenue ,Chief Financial ,Terminal Payment ,Oak Capital Partners ,Third Quarter ,Nine Months Ended ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Annual Report ,Current Reports ,Quarterly Reports ,Balance Sheet Data ,Cash Flow Data ,Nine Months ,Markets ,